Morgan Stanley Infrastructure Partners Agrees to Sell Seven Seas Water
NEW YORK--(BUSINESS WIRE)--Morgan Stanley Investment Management (MSIM), through investment funds managed by Morgan Stanley Infrastructure Partners (MSIP), its private infrastructure investment platform, today announced it has entered into an agreement to sell its ownership stake in Seven Seas Water Group (Seven Seas Water or the Company) to the EQT Infrastructure VI fund (EQT).
Seven Seas Water Group is a developer, owner, and operator of water and wastewater treatment plants across North America, including the United States, the Caribbean, and Latin America, with over 220 plants currently under management. Through its Water-as-a-Service® (WaaS®) model, the Company delivers reliable, safe, and environmentally compliant water and wastewater treatment to a diverse customer base, including governmental, municipal, industrial and hospitality clients. The Company's desalination and wastewater treatment plants sign long-term, inflation-linked contracts with take-or-pay minimum volume commitments creating stable, predictable cashflows. Operating in some of the most water-challenged geographies, Seven Seas Water ensures availability for potable and clean water, while maintaining its more than 20-year track record of high uptime, strong customer retention and a world-class health, safety, and environmental (HSE) performance.
The Company is the result of a business separation from non-infrastructure activities which was conducted shortly after a public-to-private transaction. Under MSIP's ownership, Seven Seas Water has experienced substantial growth expanding its footprint in the United States, particularly Texas, scaling to become the North American Water-as-a-Service® leader. The Company recently secured several high-profile long-term contracts, including with the South Texas Water Authority (STWA), as well as successful project delivery for the City of Alice in Texas.
'Seven Seas Water exemplifies the infrastructure characteristics we prioritize – essential services, long-term inflation-protected cashflows, and operational excellence,' said Alberto Donzelli, Managing Director and Co-Head of Europe for Morgan Stanley Infrastructure Partners. 'The Company's Water-as-a-Service® model has proven highly effective across diverse markets, and we are proud to have supported their evolution into a market-leading platform.'
Markus Hottenrott, Chief Investment Officer for Morgan Stanley Infrastructure Partners, added: 'Seven Seas Water is another example of MSIP's differentiated ability to execute corporate carve-outs and business separations, successfully conduct take-private transactions, build institutional-grade platforms and work with management teams to drive operational excellence. We are pleased to have created a resilient infrastructure business that delivers an essential service to communities and industries across North America and beyond.'
About Seven Seas Water Group
Seven Seas Water offers WaaS® solutions by providing outsourced water treatment and wastewater treatment and reuse solutions for governmental, municipal, industrial, property developer and hospitality customers. The Company's water treatment solutions utilize seawater reverse osmosis and other purification technologies to produce potable and high purity industrial process water in high volumes for customers operating in regions with limited access to potable water. Seven Seas Water's wastewater treatment and reuse solutions include scalable modular treatment plants, field-erected treatment plants and temporary bypass plants that are used by our customers to treat and convert wastewater into effluent or reclaimed water prior to being released back into the environment. Some of the Company's wastewater and reuse solutions are provided by AUC Group, a Houston, TX based subsidiary.
About Morgan Stanley Infrastructure Partners
Morgan Stanley Infrastructure Partners (MSIP) is a leading global private infrastructure investment platform with approximately $18 billion in assets under management since inception. Founded in 2006, MSIP has invested in a diverse portfolio of over 40 investments across transport, digital infrastructure, energy transition and utilities. MSIP targets assets that provide essential public goods and services with the potential for value creation through active asset management. For further information about Morgan Stanley Infrastructure Partners, please visit www.morganstanley.com/im/infrastructurepartners.
Morgan Stanley Investment Management, together with its investment advisory affiliates, has more than 1,400 investment professionals around the world and $1.6 trillion in assets under management or supervision as of March 31, 2025. Morgan Stanley Investment Management strives to provide outstanding long-term investment performance, service, and a comprehensive suite of investment management solutions to a diverse client base, which includes governments, institutions, corporations and individuals worldwide. For further information about Morgan Stanley Investment Management, please visit www.morganstanley.com/im.
About Morgan Stanley
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For further information about Morgan Stanley, please visit www.morganstanley.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
44 minutes ago
- Yahoo
American Resources Corporation Reaffirms Compliance With Nasdaq Listing Standards
FISHERS, IN / / June 10, 2025 / American Resources Corporation (NASDAQ:AREC) ("American Resources"), a leader in the critical mineral supply chain, reaffirms compliance with Nasdaq Listing Standards as outlined in the Company's Form 8-K filed on May 30, 2025 with the U.S. Securities and Exchange Commission. As stated in the in the referenced filing: On May 29, 2025, American Resources Corporation (or the "Company") received a letter from the Nasdaq Stock Market indicating that the company's Form 10-Q for the fiscal year ended March 31, 2025 has not been timely filed according to Nasdaq's Listing Rules. The Company filed the required 10-Q on May 28 and was in compliance with Nasdaq Continued Listing Standards at the time of the issuance of the notification. Mark Jensen, CEO and Chairman commented, "Transparency, governance and compliance is a paramount focus of our team. We have greatly appreciated our collaborative relationship with Nasdaq as shown by the recent spotlight interview." Watch the full interview with American Resources' Chairman and CEO Mark Jensen here. About American Resources Corporation American Resources Corporation is a next-generation, environmentally and socially responsible supplier of high-quality raw materials to the new infrastructure market. The Company is focused on the extraction and processing of metallurgical carbon, an essential ingredient used in steelmaking, critical and rare earth minerals for the electrification market, and reprocessed metal to be recycled. American Resources has a growing portfolio of operations located in the Central Appalachian basin of eastern Kentucky and southern West Virginia where premium quality metallurgical carbon and rare earth mineral deposits are concentrated. American Resources has established a nimble, low-cost business model centered on growth, which provides a significant opportunity to scale its portfolio of assets to meet the growing global infrastructure and electrification markets while also continuing to acquire operations and significantly reduce their legacy industry risks. Its streamlined and efficient operations are able to maximize margins while reducing costs. For more information visit or connect with the Company on Facebook, Twitter, and LinkedIn. About ReElement Technologies Corporation ReElement Technologies Corporation, a portfolio company of American Resources Corporation (NASDAQ:AREC), is a leading provider of high-performance refining capacity for rare earth and critical battery elements. Its multi-mineral, multi-feedstock platform technology focuses on the refining of recycled material from rare earth permanent magnets and lithium-ion batteries, concentrated ores and brines, as well as coal-based waste streams and byproducts to create a cost effective and environmentally-safe, circular supply chain. ReElement has developed its innovative and scalable "Powered by ReElement" process which collaboratively utilizes its exclusively licensed intellectual property within its partners' material processing flow sheets to more efficiently support the global supply chain's growing demand for magnet and battery-grade products. For more information visit or connect with the Company on Facebook, Twitter, and LinkedIn. Learn more about ReElement Technologies' process and technology here - Video. Special Note Regarding Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved. Investor Contact:JTC Team, LLCJenene Thomas908-824-0775AREC@ Media Inquiries:Marjorie Weisskohl703-587-1532mweisskohl@ Company Contact:Mark LaVerghetta317-855-9926 ext. 0investor@ SOURCE: American Resources Corporation View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution
Safe Group announces FDA 510(k) clearance for SpineUp's Frida solution Fleurieux-sur-l'Arbresle - France - June 5, 2025 at 6 p.m. Safe Group, a leading player in the field of medical devices for spine surgery, is pleased to announce that Frida, the innovative cervical plate developed by SpineUp, has received 510(k) clearance from the Food and Drug Administration (FDA). This clearance marks a crucial step in SpineUp's expansion into the North American market, and testifies to its ongoing commitment to providing cutting-edge medical solutions. Frida is a new-generation cervical plate offering high adaptability with a multiplicity of plate and screw sizes. Thanks to this technology, healthcare professionals will be able to offer more personalized treatments, tailored to the specific needs of surgeons and their patients. FDA 510(k) clearance is the result of several years of research and development. This certification attests to the safety and efficacy of the Frida solution, which complies with the FDA's strict standards and is due to be marketed by the end of the year. « In view of the merger of Safe's subsidiaries with SpineUp, we are delighted that this authorization has been granted and that SpineUp has taken a major step forward, validating the company's commitment to innovation and improving patient care," says Victor Humberdot, Chairman of Safe Group. 'This new step heralds new business opportunities for SpineUp and its subsidiaries Safe Orthopaedics and Safe Medical, increased synergy and a stronger foothold in the U.S.' comments Philippe Laurito, President of SpineUp Inc. About Safe Group Safe Group is a French medical technology group that brings together Safe Orthopaedics, a pioneer in ready-to-use technologies for spine pathologies, and Safe Medical (formerly LCI Medical), a medical device subcontractor for orthopedic surgeries. The group employs approximately 100 Orthopaedics develops and manufactures kits combining sterile implants and ready-to-use instruments, available at any time to the surgeon. These technologies are part of a minimally invasive approach aimed at reducing the risks of contamination and infection, in the interest of the patient and with a positive impact on hospitalization times and costs. Protected by 15 patent families, SteriSpineTM kits are CE marked and FDA approved. Safe Orthopaedics has subsidiaries in the United Kingdom, Germany, the United more information: Safe Medical produces implantable medical devices and ready-to-use instruments. It has an innovation center and two production sites in France and in Tunisia, offering numerous industrial services: industrialization, machining, finishing and sterile more information: ContactsSAFE GROUP AELYON ADVISORSinvestors@ safe@ Attachment Safe_PR_SpineUp_FDA
Yahoo
an hour ago
- Yahoo
Medincell to Present 2024-2025 Annual Results on June 17, 2025
MONTPELLIER, France, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange. The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders: French session: 6:00pm CEST / 12:00pm ET> English session: 7:00pm CEST / 1:00pm ET> During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@ or asked live during the videoconferences. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. View source version on Contacts David Heuzé Head of Corporate and Financial Communications, and / +33 (0)6 83 25 21 86Grace Kim Chief Strategy Officer, U.S. / +1 (646) 991-4023Nicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@ / +33 (0)1 44 71 94 94Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@ / +33 (0)1 44 71 94 94 Sign in to access your portfolio
